Loading
SSGJ-612 is an experimental monoclonal antibody from Shenyang Sunshine Pharmaceutical in phase 2 trials, aimed at HER2.
SSGJ-612 is a monoclonal antibody developed by Shenyang Sunshine Pharmaceutical. Its target is HER2. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT07646626, plans to enrol 150 participants with primary completion expected 2027-06-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Monoclonal antibody directed at HER2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated. Connects to HER2.
1.SSGJ-612 binds HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"SSGJ-612" OR ABSTRACT:"SSGJ-612") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SSGJ-612, not a curated reading list.
Shares SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors, 3SBio, HER2 and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares 3SBio and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.